Chen Xiaoxi, Lai Xiangwen, Wu Caixia, Tian Qingxin, Lei Tingting, Pan Jingye, Huang Guoyu
Department of Gastrointestinal Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Medical Records and Statistics, The Fifth People's Hospital, Chengdu, Sichuan, China.
Cancer Biomark. 2017 Jul 4;19(4):419-424. doi: 10.3233/CBM-160419.
Members of the SIRT family are a highly conserved family of NAD+-dependent enzymes, many of which (SIRT1-7) play an important role in tumor formation. Recently, several studies have suggested that SIRT4 not only regulates glutamine metabolism, but also serves as a tumor suppressor. There are no studies have assessed its clinical significance in endometrioid adenocarcinoma.
We investigated SIRT4 protein levels in endometrioid adenocarcinoma and its possible association with selected clinico-pathological parameters by immunohistochemical staining of a tissue microarray that included 65 endometrioid adenocarcinoma patients.
SIRT4 protein levels in endometrioid adenocarcinoma were markedly lower than its non-neoplastic tissue counterpart (P< 0.001). Moreover, lower SIRT4 expression levels were observed in advanced AJCC stages of development (P= 0.002).
Our results indicated that SIRT4 may be involved in the development of endometrioid adenocarcinoma and is a promising target for both the diagnosis and potential therapy of endometrioid adenocarcinoma.
沉默调节蛋白（SIRT）家族成员是一类高度保守的烟酰胺腺嘌呤二核苷酸（NAD +）依赖性酶，其中许多成员（SIRT1 - 7）在肿瘤形成中发挥重要作用。最近，多项研究表明，SIRT4不仅调节谷氨酰胺代谢，还具有肿瘤抑制作用。目前尚无研究评估其在子宫内膜样腺癌中的临床意义。
我们通过对包含65例子宫内膜样腺癌患者的组织芯片进行免疫组化染色，研究了子宫内膜样腺癌中SIRT4蛋白水平及其与选定临床病理参数的可能关联。
子宫内膜样腺癌中SIRT4蛋白水平明显低于其非肿瘤组织对应物（P < 0.001）。此外，在晚期美国癌症联合委员会（AJCC）分期中观察到较低的SIRT4表达水平（P = 0.002）。
我们的结果表明，SIRT4可能参与子宫内膜样腺癌的发生发展，是子宫内膜样腺癌诊断和潜在治疗的一个有前景的靶点。
